MK3207 for Treatment of Acute Migraines (3207-005)

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Men and Women from 18 to 65 years of age

• 1+ year history of migraine that typically last from 4 to 72 hours if untreated

• Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months

• Not pregnant or planning to become pregnant in next 6 months

Exclusion Criteria:

• Pregnant or breast-feeding, or planning to become pregnant in next 6 months

• Cannot distinguish migraine attacks from tension type headaches

• Migraines are mild or resolve without medication in less than 2 hours

• More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months

• Basilar type or hemiplegic migraine headaches

• More than 50 years old when migraines began

• History of cardiovascular disorder within last 6 months